Callan JMB Announces Second Quarter 2025 Financial Results and Provides Business Update
Callan JMB (NASDAQ: CJMB), a healthcare logistics company, reported Q2 2025 financial results and significant business developments. The company recorded Q2 revenues of $1.7 million and a net loss from operations of $1.4 million.
Key developments include a strategic partnership with Revival Health for integrated supply chain services, launch of an Indian subsidiary with planned temperature-controlled facilities in Pune, and extension of Chicago's emergency preparedness contract through June 2026 with a $1.5 million funding increase to $9.1 million total. The company also appointed Christopher Shields as SVP of Emergency Preparedness & Response and successfully managed a measles outbreak response.
Post-quarter, Callan JMB secured a $25 million equity line of credit to support growth initiatives in GLP-1 pharmaceutical distribution, specialty compounding pharmacy logistics, and premium food packaging solutions.
Callan JMB (NASDAQ: CJMB), società di logistica sanitaria, ha comunicato i risultati finanziari del secondo trimestre 2025 e importanti sviluppi aziendali. La società ha registrato ricavi del secondo trimestre pari a 1,7 milioni di dollari e un perdita netta operativa di 1,4 milioni di dollari.
Tra le novità principali, una partnership strategica con Revival Health per servizi integrati di supply chain, l’avvio di una controllata in India con previsione di strutture a temperatura controllata a Pune, e l’estensione del contratto di preparazione alle emergenze di Chicago fino a giugno 2026 con un incremento di finanziamento di 1,5 milioni di dollari, portando il totale a 9,1 milioni. L’azienda ha inoltre nominato Christopher Shields come SVP Emergency Preparedness & Response e ha gestito con successo una risposta a un focolaio di morbillo.
Successivamente alla chiusura del trimestre, Callan JMB ha ottenuto una linea di credito azionaria da 25 milioni di dollari per sostenere iniziative di crescita nella distribuzione di farmaci GLP‑1, nella logistica per farmacie di compound specializzate e nelle soluzioni di packaging alimentare premium.
Callan JMB (NASDAQ: CJMB), una empresa de logística sanitaria, informó los resultados financieros del segundo trimestre de 2025 y relevantes avances comerciales. La compañía registró ingresos del 2T de 1,7 millones de dólares y una pérdida neta operativa de 1,4 millones de dólares.
Los hitos clave incluyen una alianza estratégica con Revival Health para servicios integrados de la cadena de suministro, el lanzamiento de una filial en India con instalaciones previstas a temperatura controlada en Pune, y la prórroga del contrato de preparación ante emergencias de Chicago hasta junio de 2026 con un aumento de financiación de 1,5 millones de dólares, hasta un total de 9,1 millones. La compañía también nombró a Christopher Shields como SVP de Emergency Preparedness & Response y gestionó con éxito la respuesta a un brote de sarampión.
Tras el cierre del trimestre, Callan JMB aseguró una línea de crédito en acciones de 25 millones de dólares para apoyar iniciativas de crecimiento en distribución farmacéutica de GLP‑1, logística de farmacias de formulación especializada y soluciones de envasado alimentario premium.
Callan JMB (NASDAQ: CJMB), 의료 물류 회사는 2025년 2분기 실적과 주요 사업 진행 사항을 발표했습니다. 회사는 2분기 매출 170만 달러와 영업 순손실 140만 달러를 기록했습니다.
주요 내용으로는 통합 공급망 서비스를 위한 Revival Health와의 전략적 파트너십, 푸네에 온도 제어 시설을 계획한 인도 법인 출범, 시카고의 비상 대비 계약을 2026년 6월까지 연장하고 자금 150만 달러 증액으로 총 910만 달러로 확대한 점이 포함됩니다. 또한 Christopher Shields를 비상 대비 및 대응 담당 수석부사장(SVP)으로 임명했으며 홍역 발생 대응을 성공적으로 수행했습니다.
분기 마감 후 Callan JMB는 GLP‑1 의약품 유통, 전문 조제 약국 물류, 고급 식품 포장 솔루션 등의 성장 이니셔티브를 지원하기 위해 2,500만 달러 규모의 주식 담보 신용한도를 확보했습니다.
Callan JMB (NASDAQ: CJMB), entreprise de logistique sanitaire, a publié ses résultats du deuxième trimestre 2025 et des avancées commerciales importantes. La société a affiché des revenus du T2 de 1,7 million de dollars et une perte nette d'exploitation de 1,4 million de dollars.
Parmi les faits marquants figurent un partenariat stratégique avec Revival Health pour des services intégrés de chaîne d'approvisionnement, le lancement d'une filiale en Inde avec des installations en température contrôlée prévues à Pune, et la prolongation du contrat de préparation aux urgences de Chicago jusqu'en juin 2026 avec une augmentation de financement de 1,5 million de dollars, portant le total à 9,1 millions. L'entreprise a également nommé Christopher Shields SVP Emergency Preparedness & Response et a géré avec succès une réponse à une épidémie de rougeole.
Après la clôture du trimestre, Callan JMB a obtenu une ligne de crédit en actions de 25 millions de dollars pour soutenir des initiatives de croissance dans la distribution de médicaments GLP‑1, la logistique des pharmacies de préparation spécialisée et les solutions d'emballage alimentaire haut de gamme.
Callan JMB (NASDAQ: CJMB), ein Unternehmen für Gesundheitslogistik, veröffentlichte die Finanzergebnisse für das zweite Quartal 2025 sowie bedeutende Geschäftsentwicklungen. Das Unternehmen erzielte Umsätze im 2. Quartal von 1,7 Millionen US‑Dollar und einen operativen Nettoverlust von 1,4 Millionen US‑Dollar.
Wesentliche Entwicklungen sind eine strategische Partnerschaft mit Revival Health für integrierte Lieferketten‑Dienstleistungen, die Gründung einer Tochtergesellschaft in Indien mit geplanten temperaturkontrollierten Einrichtungen in Pune sowie die Verlängerung des Notfallvorsorgevertrags in Chicago bis Juni 2026 bei einer Finanzierungserhöhung von 1,5 Millionen auf insgesamt 9,1 Millionen US‑Dollar. Das Unternehmen berief zudem Christopher Shields zum SVP Emergency Preparedness & Response und bewältigte erfolgreich eine Masern‑Ausbruchreaktion.
Nach Quartalsende sicherte sich Callan JMB eine 25‑Millionen‑Dollar‑Eigenkapitallinie, um Wachstumsinitiativen in der GLP‑1‑Arzneimittelvertrieb, der Logistik für spezialisierte Rezepturapotheken und hochwertigen Lebensmittelverpackungslösungen zu unterstützen.
- Secured $25 million equity line of credit for growth financing
- Extended Chicago contract with $1.5 million additional funding to $9.1 million total
- Established strategic partnership with Revival Health for integrated supply chain services
- Expanded internationally with new Indian subsidiary and secured agreement with Walker's Pharmaceuticals
- Demonstrated operational excellence with zero-waste vaccine redistribution during measles outbreak
- Revenue decreased year-over-year due to declining emergency preparedness service demand
- Operating loss of $1.4 million in Q2 2025
- Increased SG&A expenses due to public company costs and executive compensation
- Cash position decreased to $4.2 million
Insights
Callan JMB reports declining revenue despite strategic expansion efforts, with Q2 losses as emergency services demand drops.
Callan JMB's Q2 2025 results show concerning financial performance, with quarterly revenue of
Despite these challenges, the company is executing a multi-pronged expansion strategy. Their new partnership with Revival Health establishes integrated supply chain infrastructure for health and longevity products. The company has also launched operations in India with plans for temperature-controlled pharmaceutical warehousing in Pune, securing an initial agreement with Walker's Pharmaceuticals.
On the government contracting front, Callan JMB extended its Chicago emergency preparedness contract through June 2026, increasing the total contract value to
The company's increasing SG&A expenses (
While management is positioning these initiatives as growth catalysts—particularly in GLP-1 pharmaceutical distribution, specialty pharmacy logistics, and premium food packaging—the current financial performance demonstrates execution challenges as the company transitions from emergency response to broader logistics services.
Formed a strategic partnership with Revival Health Inc. (“Revival”) to deliver fully integrated supply chain services and infrastructure to support both the importation and onshore manufacturing of health, wellness, and longevity products
Launched subsidiary in India and progressed to establish temperature-controlled warehouse for storage and distribution of pharmaceuticals at all temperature ranges
Extended long-term contract with City of Chicago and received increase in funding
Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs
Supported Texas and New Mexico with measles outbreak response through redistribution of MMR II vaccines
SPRING BRANCH, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the second quarter ended June 30, 2025 and provided a business update.
"Callan JMB continues to solidify its position as a leading provider of specialized logistics solutions within high-growth opportunity markets, demonstrating our operational excellence through several key recent achievements," commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. "We were proud to form a strategic partnership with Revival to develop a broad supply platform for healthcare products, changing the way they are made available across the country. In July, we further expanded our market for global pharmaceutical cold chain logistics and clinical trial support by launching a subsidiary in India to establish temperature-controlled warehouses for storage and distribution. This international expansion positions us to import critical tissue samples for clinical trials and active pharmaceutical ingredients, helping address U.S. drug shortages.”
“Furthermore, we recently extended our emergency preparedness contract with the City of Chicago through June 2026 with
Business Highlights:
- Formed strategic partnership with Revival to create integrated supply chain infrastructure for health, wellness, and longevity products, combining cold chain logistics expertise with consumer health innovation for scalable distribution solutions.
- Post quarter end launched Callan JMB Services (India) Private Limited with planned temperature-controlled warehouse in Pune, Maharashtra for pharmaceutical storage and distribution, already securing an agreement with Walker's Pharmaceuticals Ltd. and working with additional Indian companies to facilitate U.S. market entry and manufacturing plant establishment.
- In July, the City of Chicago extended Callan JMB's emergency preparedness contract through June 2026 with
$1.5 million funding increase, bringing total contract value to$9.1 million and extending the seven-year partnership for continued management and distribution of health preparedness supplies. - Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs.
- Successfully redistributed over 1,300 MMR II vaccine doses from Chicago to Texas and New Mexico during measles outbreak response using specialized cold chain reusable shippers with zero waste, demonstrating emergency response capabilities and sustainable logistics solutions.
Financial Highlights for the Year Ended June 30, 2025:
- Revenues for the three months and six months ended June 30, 2025 were
$1.7 million and$3.1 million , respectively. The decrease year-over-year in revenue was due to the decline in demand for our emergency preparedness services by certain states and local governments. - Cost of revenues for the three months and six months ended June 30, 2025 were
$1.0 million and 1.9 million, respectively. The decrease year-over-year in cost of revenue is in line with the decrease in revenues. - Gross profit for the three months and six months ended June 30, 2025 were
$0.6 million and 1.3 million, respectively. - SG&A expenses for the three months and six months ended June 30, 2025 were
$2.0 million and$3.9 million . The increase year-over-year was primarily driven by an increase in consulting, professional fees and marketing expenses related to the Company now being a public entity and adding the Company’s CEO to payroll for the first time, along with other senior staff hires to support future growth. - Loss from operations for the three months and six months ended June 30, 2025 were
$1.4 million and$2.6 million , respectively. - Cash and cash equivalents for the period ended June 30, 2025 were
$4.2 million . - Subsequent to quarter end, the Company entered into an equity line of credit agreement with an investor for the right to sell up to
$25 million of shares of the Company’s common stock.
About Callan JMB Inc.
Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254
CALLAN JMB INC.
(Formerly known as Coldchain Technology Services, LLC)
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2025 (Unaudited) | December 31, 2024 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 4,224,151 | $ | 2,097,945 | ||||
| Accounts receivable, net of allowance for credit losses of | 614,211 | 622,914 | ||||||
| Inventory | 197,506 | 158,362 | ||||||
| Related party loans | - | 18,669 | ||||||
| Tax refund receivable | - | 6,377 | ||||||
| Prepaid insurance | 75,478 | 151,354 | ||||||
| Other current assets | 478,902 | 127,542 | ||||||
| Deferred offering costs | - | 136,025 | ||||||
| Total current assets | 5,590,248 | 3,319,188 | ||||||
| Right of use assets – operating lease | 2,127,646 | 883,029 | ||||||
| Property and equipment, net of accumulated depreciation of | 1,247,787 | 876,682 | ||||||
| Security deposit | - | 3,650 | ||||||
| Total assets | $ | 8,965,681 | $ | 5,082,549 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 430,859 | $ | 371,661 | ||||
| Accrued expenses | 518,776 | 506,381 | ||||||
| Corporate taxes payable | 30,508 | 23,000 | ||||||
| Deferred revenue | 2,018 | 94,097 | ||||||
| Operating lease liabilities – current | 329,278 | 279,176 | ||||||
| Total current liabilities | 1,311,439 | 1,274,315 | ||||||
| Operating lease liabilities – non-current | 1,828,955 | 628,274 | ||||||
| Deferred tax liabilities | - | 6,602 | ||||||
| Total long-term liabilities | 1,828,955 | 634,876 | ||||||
| Total liabilities | 3,140,394 | 1,909,191 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity | ||||||||
| Preferred stock - authorized 10,000,000 shares, | $ | - | $ | - | ||||
| Common stock - authorized 190,000,000 shares, par value | 4,482 | 3,000 | ||||||
| Additional Paid in Capital | 10,756,439 | 5,464,006 | ||||||
| Accumulated Deficit | (4,935,634 | ) | (2,293,648 | ) | ||||
| Total Stockholders’ Equity | 5,825,287 | 3,173,358 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 8,965,681 | $ | 5,082,549 | ||||
CALLAN JMB INC.
(Formerly known as Coldchain Technology Services, LLC)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| Three months ended | Six months ended | |||||||||||||||
| June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 | |||||||||||||
| Revenue | $ | 1,666,309 | $ | 1,985,768 | $ | 3,115,687 | $ | 3,776,289 | ||||||||
| Cost of revenue | 1,022,439 | 1,023,552 | 1,858,724 | 2,096,490 | ||||||||||||
| Gross profit | 643,870 | 962,216 | 1,256,963 | 1,679,799 | ||||||||||||
| Selling, general and administrative expenses | 2,046,537 | 1,095,639 | 3,901,878 | 1,900,681 | ||||||||||||
| Loss from operations | (1,402,667 | ) | (133,423 | ) | (2,644,915 | ) | (220,882 | ) | ||||||||
| Other income (expenses) | ||||||||||||||||
| Interest income | 2,042 | 2,753 | 4,251 | 6,187 | ||||||||||||
| Interest expense | - | (1,806 | ) | (63 | ) | (4,914 | ) | |||||||||
| Total other income (expenses) | 2,042 | 947 | 4,188 | 1,273 | ||||||||||||
| Loss before income taxes | (1,400,625 | ) | (132,476 | ) | (2,640,727 | ) | (219,609 | ) | ||||||||
| Provision (benefit) for income taxes | (3,102 | ) | (20,000 | ) | 1,259 | (26,000 | ) | |||||||||
| Net loss | $ | (1,397,523 | ) | $ | (112,476 | ) | $ | (2,641,986 | ) | $ | (193,609 | ) | ||||
| Weighted average common shares outstanding - basic and diluted | 4,456,962 | 3,000,000 | 4,167,828 | 2,483,333 | ||||||||||||
| Net loss per common share - basic and diluted | $ | (0.31 | ) | $ | (0.04 | ) | $ | (0.63 | ) | $ | (0.08 | ) | ||||
CALLAN JMB INC.
(Formerly known as Coldchain Technology Services, LLC)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Six months ended | |||||||||
| June 30, 2025 | June 30, 2024 | ||||||||
| Cash flows from operating activities: | |||||||||
| Net loss | $ | (2,641,986 | ) | $ | (193,609 | ) | |||
| Adjustment to reconcile net loss to net cash provided by (used in) operating activities: | |||||||||
| Depreciation | 76,401 | 72,428 | |||||||
| Provision (recoveries) for credit losses | (7,666 | ) | - | ||||||
| Stock based compensation | 749,927 | - | |||||||
| Changes in operating assets and liabilities: | |||||||||
| Accounts receivable | 16,369 | 63,329 | |||||||
| Inventory | (39,144 | ) | (4,412 | ) | |||||
| Tax refund receivable | 6,377 | - | |||||||
| Other current assets | (271,834 | ) | 85,540 | ||||||
| Operating lease liabilities | 6,166 | 1,952 | |||||||
| Accounts payable and accrued expenses | 71,593 | 282,352 | |||||||
| Deferred revenue | (92,079 | ) | (6,056 | ) | |||||
| Deferred tax liabilities | (6,602 | ) | - | ||||||
| Corporate taxes payable | 7,508 | (26,000 | ) | ||||||
| Net cash provided by (used in) operating activities | $ | (2,124,970 | ) | $ | 275,524 | ||||
| Cash flows used in investing activity: | |||||||||
| Purchase of property and equipment | (447,506 | ) | (45,874 | ) | |||||
| Net cash used in investing activity | $ | (447,506 | ) | $ | (45,874 | ) | |||
| Cash flows from (used in) financing activities: | |||||||||
| Related party loans | 18,669 | (17,073 | ) | ||||||
| Deferred offering costs | - | (65,000 | ) | ||||||
| Partner distributions | - | (3,382,254 | ) | ||||||
| Decrease in note payable | - | (73,222 | ) | ||||||
| Proceeds from IPO and overallotment, net | 4,680,013 | - | |||||||
| Net cash provided by (used in) financing activities | $ | 4,698,682 | $ | (3,537,549 | ) | ||||
| Increase (decrease) in cash and cash equivalents | 2,126,206 | (3,307,899 | ) | ||||||
| Cash and cash equivalents at beginning of period | 2,097,945 | 5,155,620 | |||||||
| Cash and cash equivalents at end of period | $ | 4,224,151 | $ | 1,847,721 | |||||
FAQ
What were Callan JMB's (CJMB) Q2 2025 financial results?
How much is Callan JMB's new contract with the City of Chicago worth?
What is Callan JMB's expansion plan in India?
How much funding did Callan JMB secure through its equity line of credit?
Who is Christopher Shields and what is his role at Callan JMB?
How did Callan JMB support the measles outbreak response?
